Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AS Latvijas Juras medicinas centrs's Enterprise Value for the quarter that ended in Dec. 2025 was €5.97 Mil.
AS Latvijas Juras medicinas centrs's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AS Latvijas Juras medicinas centrs EV-to-EBIT Related Terms
AS Latvijas Juras medicinas centrs EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AS Latvijas Juras medicinas centrs EV-to-EBIT Chart
ORSE:LJM1R vs HCA, THC, ENSG: EV-to-EBIT Comparison
For the Medical Care Facilities subindustry, AS Latvijas Juras medicinas centrs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AS Latvijas Juras medicinas centrs EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, AS Latvijas Juras medicinas centrs's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AS Latvijas Juras medicinas centrs's EV-to-EBIT falls into.
AS Latvijas Juras medicinas centrs's current Enterprise Value is €5.09 Mil.
AS Latvijas Juras medicinas centrs's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a EV-to-EBIT of 44.63 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AS Latvijas Juras medicinas centrs and its competitors. This is 214% above median its historical median of 14.21.
Is AS Latvijas Juras medicinas centrs' EV-to-EBIT too high?
AS Latvijas Juras medicinas centrs' current EV-to-EBIT of 44.63 is 214% above median its 10-year median of 14.21. The Healthcare Providers & Services industry median EV-to-EBIT is 15.75. AS Latvijas Juras medicinas centrs' value of 44.63 is 183.4% above this industry median. Overall, AS Latvijas Juras medicinas centrs has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does AS Latvijas Juras medicinas centrs' EV-to-EBIT compare to HCA and THC?
AS Latvijas Juras medicinas centrs' EV-to-EBIT of 44.63 can be compared against companies in the Healthcare Providers & Services industry. The industry median EV-to-EBIT is 15.75. AS Latvijas Juras medicinas centrs' value of 44.63 is 183.4% above this benchmark. While the company's 10-year median is 14.21 vs. the industry median of 15.75, AS Latvijas Juras medicinas centrs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.75, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AS Latvijas Juras medicinas centrs's current EV-to-EBIT of 44.63 is 183.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AS Latvijas Juras medicinas centrs and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AS Latvijas Juras medicinas centrs's current EV-to-EBIT is 44.63, which is 214% above median its own 10-year median of 14.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AS Latvijas Juras medicinas centrs stock overvalued right now?
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a current EV-to-EBIT of 44.63. The stock's GF Value™ is €7.78, compared to a current price of €7.80 — trading 0.3% above its estimated fair value. The current EV-to-EBIT is 44.63, which is 214% above median its 10-year median of 14.21 and 183.4% above the Healthcare Providers & Services industry median of 15.75. AS Latvijas Juras medicinas centrs' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AS Latvijas Juras medicinas centrs (ORSE:LJM1R), the current EV-to-EBIT is 44.63 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Overvalued in 2026?
Based on GuruFocus' analysis, AS Latvijas Juras medicinas centrs stock appears to be overvalued.
The current stock price of €7.80 is trading 0.3% above its estimated GF Value™ of €7.78.
Key valuation signals for ORSE:LJM1R:
EV-to-EBIT: 44.63 (214% above median its 10-year median of 14.21)
GF Value™: €7.78 vs. price of €7.80 (0.3% above fair value)
Industry Position: 183.4% above the Healthcare Providers & Services median
No single metric tells the full story. See the ORSE:LJM1R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AS Latvijas Juras medicinas centrs is a private certified medical institution in Latvia providing outpatient and inpatient healthcare services through qualified staff and modern equipment. Its core activities include hospital services, orthopaedic retail, medical and dental practice, human health and residential care, social work activities, and physical well-being services. It operates the Women's Health Clinic, offering gynecological consultations, pregnancy care, diagnostics, postpartum services, gynecological care for girls, and surgery. The centre also provides vaccination, rehabilitation, a Multiple Sclerosis Center, medical commission, home visits, laboratory services, physical medicine and massage, therapeutic procedures, medical treatment, and anesthesia and intensive care.
59GF Score
Get the complete analysis for ORSE:LJM1R
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORSE:LJM1R has been successfully added to your 
